In Vitro Nonalcoholic Fatty Liver Disease Model Elucidating the Effect of Immune Environment on Disease Progression and Alleviation
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD), which is a major cause of chronic liver disease, is characterized by fat accumulation in the liver. Existing models struggle to assess medication effects on liver function in the context of NAFLD's unique inflammatory environment. We address this by developing a 3D in vitro NAFLD model using HepG2 and THP-1 cells (mimicking liver and Kupffer cells) cocultured using transwell and hydrogel system. This mimics liver architecture and allows for manipulation of the immune environment. We demonstrate that the model recapitulates key NAFLD features: steatosis (induced by fatty acids), oxidative stress, inflammation, and impaired liver function embodying the interrelationship between NAFLD and the surrounding immune environment. This versatile model offers a valuable tool for preclinical NAFLD research by incorporating a disease-relevant immune environment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MASLD modeling using co-cultures aims to reproduce the tissue microenvironment of the liver, including intercellular interactions between hepatocytes and non-parenchymal cells (stellate, immune), which is a key factor in the progression from steatosis to steatohepatitis and fibrosis [132,133,134].”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [133]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In more complex systems (3D cultures, co-cultures), lower FFA concentrations (10–500 μM) are required [131,132,133,134], which brings conditions closer to physiological ones and reduces the risk of non-specific cytotoxicity.”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [133]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383
Energy Metabolism in the Liver
Rui, L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130024 · Cited by 1,953
Coutinho, A. E., & Chapman, K. E. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.04.005 · Cited by 1,815
Oxidative stress as a crucial factor in liver diseases
Cichoż-Lach, H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i25.8082 · Cited by 1,216
The Role of Reactive Oxygen Species (ROS) in the Biological Activities of Metallic Nanoparticles
Abdal Dayem, A., Hossain, M., Lee, S., Kim, K., Saha, S., Yang, G.-M., Choi, H., & Cho, S.-G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010120 · Cited by 1,141
Increased Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis
Wieckowska, A., Papouchado, B. G., Li, Z., Lopez, R., Zein, N. N., & Feldstein, A. E. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01774.x · Cited by 597
Non-alcoholic fatty liver disease: The diagnosis and management
El-Kader, S. M. A. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i6.846 · Cited by 381
Adipocyte lipolysis: from molecular mechanisms of regulation to disease and therapeutics
Yang, A., & Mottillo, E. P. (2020) · Biochemical Journal · doi:10.1042/bcj20190468 · Cited by 246
The Role of Cytokines in Non-Alcoholic Fatty Liver Disease
Tilg, H. (2010) · Digestive Diseases · doi:10.1159/000282083 · Cited by 227
Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments
Peng, C., Stewart, A. G., Woodman, O. L., Ritchie, R. H., & Qin, C. X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.603926 · Cited by 225
Non-alcoholic fatty liver disease: What the clinician needs to know
Machado, M. V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i36.12956 · Cited by 204
An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease
Pei, K., Gui, T., Kan, D., Feng, H., Jin, Y., Yang, Y., Zhang, Q., Du, Z., Gai, Z., Wu, J., et al. (2020) · BioMed Research International · doi:10.1155/2020/4020249 · Cited by 204
Tang, S.-P., Mao, X.-L., Chen, Y.-H., Yan, L.-L., Ye, L.-P., & Li, S.-W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.870239 · Cited by 184
Diagnosis of alcoholic liver disease
Torruellas, C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i33.11684 · Cited by 179
Petrescu, M. D., Vlaicu, S. I., Ciumărnean, L., Milaciu, M. V., Mărginean, C., Florea, M., Vesa, Ș. C., & Popa, M. (2022) · Medicina · doi:10.3390/medicina58050641 · Cited by 173
Impact of Dietary Palmitic Acid on Lipid Metabolism
Murru, E., Manca, C., Carta, G., & Banni, S. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.861664 · Cited by 168
MORAVCOVÁ, A., ČERVINKOVÁ, Z., KUČERA, O., MEZERA, V., RYCHTRMOC, D., & LOTKOVÁ, H. (2015) · Physiological Research · doi:10.33549/physiolres.933224 · Cited by 165
IL-1 Family Cytokine Pathways Underlying NAFLD: Towards New Treatment Strategies
Mirea, A.-M., Tack, C. J., Chavakis, T., Joosten, L. A. B., & Toonen, E. J. M. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.03.005 · Cited by 156
Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities
Idalsoaga, F., Kulkarni, A. V., Mousa, O. Y., Arrese, M., & Arab, J. P. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00448 · Cited by 136
In Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal
Soret, P.-A., Magusto, J., Housset, C., & Gautheron, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010036 · Cited by 121
Human in vitro models of nonalcoholic fatty liver disease
Müller, F. A., & Sturla, S. J. (2019) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2019.03.001 · Cited by 118 · cited 2×
“18 However, these approaches impose constraints on the specific analyses and considerations for each cell type used.”
Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression?
Tarantino, G., Sinatti, G., Citro, V., Santini, S. J., & Balsano, C. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03339-z · Cited by 116
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
Francque, S., & Vonghia, L. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00898-6 · Cited by 92
Dallio, M., Sangineto, M., Romeo, M., Villani, R., Romano, A. D., Loguercio, C., Serviddio, G., & Federico, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010436 · Cited by 83
Pinyopornpanish, K., Leerapun, A., Pinyopornpanish, K., & Chattipakorn, N. (2021) · Gut and Liver · doi:10.5009/gnl20367 · Cited by 81
Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications
Blache, U., Weiss, R., Boldt, A., Kapinsky, M., Blaudszun, A.-R., Quaiser, A., Pohl, A., Miloud, T., Burgaud, M., Vucinic, V., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658314 · Cited by 75
Hypoxia-inducible lipid droplet-associated induces DGAT1 and promotes lipid storage in hepatocytes
Rodriguez, M. A. D. L. R., Deng, L., Gemmink, A., van Weeghel, M., Aoun, M. L., Warnecke, C., Singh, R., Borst, J. W., & Kersten, S. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101168 · Cited by 74
Granitzny, A., Knebel, J., Müller, M., Braun, A. C., Steinberg, P., Dasenbrock, C., & Hansen, T. (2017) · Toxicology Reports · doi:10.1016/j.toxrep.2017.02.001 · Cited by 51
Kirovski, G., Dorn, C., Huber, H., Moleda, L., Niessen, C., Wobser, H., Schacherer, D., Buechler, C., Wiest, R., & Hellerbrand, C. (2011) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2011.08.001 · Cited by 43
What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
Tarantino, G., & Citro, V. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02031-1 · Cited by 40
Xiong, J., Chen, X., Zhao, Z., Liao, Y., Zhou, T., & Xiang, Q. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11536 · Cited by 38
Recent advances in models of immune-mediated drug-induced liver injury
Tasnim, F., Huang, X., Lee, C. Z. W., Ginhoux, F., & Yu, H. (2021) · Frontiers in Toxicology · doi:10.3389/ftox.2021.605392 · Cited by 32
Flóres, Y. N., Amoon, A. T., Su, B., Velázquez‐Cruz, R., Ramírez‐Palacios, P., Salmerón, J., Rivera‐Paredez, B., Sinsheimer, J. S., Lusis, A. J., Huertas‐Vázquez, A., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01526-5 · Cited by 32
Chen, Y., Liu, Y., Chen, S., Zhang, L., Rao, J., Lu, X., & Ma, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1180184 · Cited by 29
Innate Immune System in the Pathogenesis of Non-Alcoholic Fatty Liver Disease
Ma, D. W., Ha, J., Yoon, K., Kang, I., Choi, T. G., & Kim, S. S. (2023) · Nutrients · doi:10.3390/nu15092068 · Cited by 27
Schilcher, K., Dayoub, R., Kubitza, M., Riepl, J., Klein, K., Buechler, C., Melter, M., & Weiß, T. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713222 · Cited by 27
Ramms, B., Patel, S., Sun, X., Pessentheiner, A. R., Ducasa, G. M., Mullick, A. E., Lee, R. G., Crooke, R. M., Tsimikas, S., Witztum, J. L., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158414 · Cited by 24
Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story
Cataldi, M., Manco, F., & Tarantino, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312947 · Cited by 10
Miscellaneous drugs, materials, medical devices, and techniques
Choulis, N. H. (2009) · Side effects of drugs annual · doi:10.1016/s0378-6080(09)03149-3 · Cited by 4
Cited by
The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease
Kotlyarova, A., Iskrina, A., & Kotlyarov, S. (2026) · International journal of molecular sciences · doi:10.3390/ijms27083399 · Cited by 10
Metadata
- Authors
- Kim, I., Kyun, M.-L., Jung, H., Kwon, J.-I., Kim, J., Kim, J.-K., Lee, Y. B., Kwon, Y.-I., & Moon, K.-S.
- Affiliations
- Hannam University (KR)
- Korea Institute of Toxicology (KR)
- Corresponding author
- Lee, Yu Bin
- Kwon, Young-In
- Moon, Kyoung-Sik
- Venue
- ACS Omega
- Publisher
- American Chemical Society (ACS)
- Published
- 2024-05-27
- Volume
- 9
- Issue
- 23
- Pages
- 25094-25105
- ISSN
- 2470-1343 (ISSN-L)
- PMC
- PMC11171094
- OpenAlex
- W4399055201
- Cited by
- 10
- References
- 40
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 1
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- ACS Omega (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Korea Institute of Toxicology (1711195891)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- non-alcoholic fatty liver disease, 3D in vitro model, HepG2 cells, THP-1 cells, Kupffer cells, co-culture, hydrogels, transwell assay, steatosis, oxidative stress, liver inflammation, fatty acids, liver function
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.